

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

- 1-11. (Cancelled).
12. (Previously Presented) A composition comprising a producer cell that expresses a molecule that is an inhibitor of the growth of a CNS tumor, the cell being encapsulated in a matrix that comprises an immunoisolating alginate having a G content of above 15%, wherein the molecule is endostatin, angiostatin, thrombospondin, or prolactin; the producer cell is encapsulated in a bead or microbead; and the alginate concentration within the bead or microbead increases from the center of the bead or the microbead to the outer rim.
13. (Cancelled)
14. (Original) The composition according to claim 12, wherein the alginate has a G content of above 50%.
15. (Original) The composition according to claim 12, wherein the alginate has a G content of 60%-80%.
16. (Original) The composition according to claim 12, wherein the alginate has a G content of 80%-100%.
17. (Previously Presented) The composition according to claim 12, wherein the cell's expression of endostatin, angiostatin, thrombospondin, or prolactin is switched on and off by an external pharmacological agent.
18. (Cancelled)
19. (Previously Presented) The composition of claim 12, wherein the CNS tumor is a brain tumor.
20. (Original) The composition according to claim 12, wherein the alginate is substantially free of endotoxin.
- 21.-23. (Cancelled)
24. (Currently amended) A method of producing the composition according to claim 12, comprising introducing, in a drop-wise manner, a mixture of the producer cells that express a molecule that is endostatin, angiostatin, thrombospondin, or prolactin and the alginate into a solution containing multivalent cations.

25. (Original) A method of producing the composition according to claim 12, comprising the step of adding, in a drop-wise manner, an alginate solution containing at least one viable cell that expresses a molecule that is endostatin, angiostatin, thrombospondin, or prolactin to a calcium-containing solution.

26. (Original) A pharmaceutical composition comprising (a) the composition according to claim 12 and (b) a pharmaceutically acceptable carrier or diluent.

27. (Original) A method of treating a mammalian patient afflicted with a CNS tumor comprising the step of administering to the patient an effective amount of the pharmaceutical composition according to claim 26.

28. (Original) The method of treatment according to claim 27, wherein the CNS tumor is a brain tumor.

29. (Canceled)

30. (Previously Presented) The method according to claim 27 wherein the producer cell is encapsulated in a bead or microbead and the alginate concentration within the bead or microbead increases from the center of the bead or the microbead to the outer rim.

31. (Canceled)

32. (Previously Presented) The composition according to claim 12 wherein the producer cell comprises a plasmid that includes a nucleic acid sequence that encodes endostatin, angiostatin, thrombospondin, or prolactin.

33. (New) The method according to claim 24 wherein the solution containing multivalent cations is substantially free of sodium chloride.

34. (New) The method according to claim 25 wherein the solution containing multivalent cations is substantially free of sodium chloride.